Insulin glargine in the management of diabetes mellitus

P and T

Volumn 26, Issue 4, 2001, Pages

  Nakhmanovich, Y ^a   Belenkaya, R ^a   Rozenfeld, V ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CORTICOSTEROID; DANAZOL; DEXTROPROPOXYPHENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUOXETINE; GESTAGEN; HUMAN GROWTH HORMONE; INSULIN; INSULIN GLARGINE; ISONIAZID; ISOPHANE INSULIN; LITHIUM SALT; MONOAMINE OXIDASE INHIBITOR; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SOMATOSTATIN; SULFONAMIDE; THYROID HORMONE;

ALLERGIC REACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ALCOHOL INTERACTION; DRUG COST; DRUG DISPOSITION; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; REVIEW;

EID: 0035028112     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Pharmacologic therapy for type 2 diabetes mellitus
2. Standards of medical care for patients with diabetes mellitus
3. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
4. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple dally insulin regimen
5. Insulin glargine (HOE 901): First responsibility: Understanding the data and ensuring safety
6. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
7. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
8. Insulin glargine
9. New drug overview: Insulin glargine
10. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE1) of T1DM
11. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo
12. Insulin glargine
13. Comparison of the s.c. absorption of HOE 901 and NPH human insulin type 2 diabetic subjects
14. Pharmacokinetics of a long-acting human insulin analogue (HOE 901) in healthy subjects
15. Comparative clinical trials of new long-acting insulin (HOE 901) vs protamine insulin demonstrates less nocturnal hypoglycemia
16. The effect of HOE 901 on glycemic control in type 2 diabetes
17. Insulin glargine
18. Insulin glargine